延长西他沙星与多西环素联合方案治疗高度耐药生殖支原体感染
在日本开展的前瞻性队列研究纳入27例生殖支原体泌尿生殖道或直肠感染患者,接受西他沙星联合多西环素21天挽救治疗,总体治愈率77.8%。对同时携带parC和gyrA突变的菌株,联合方案治愈率68.8%,与单药治疗的37.5%相比P=0.053。
要点
- 21天西他沙星联合多西环素挽救治疗总体治愈率为77.8%。
- 所有可分析菌株均有parC突变(24/24)和大环内酯耐药突变(25/25),68%(17/25)有gyrA突变。
- 对同时携带parC和gyrA突变的菌株,联合方案治愈率68.8%,与单药治疗37.5%相比P=0.053。
核心结论
- 延长西他沙星与多西环素联合治疗对同时携带parC和gyrA突变的生殖支原体菌株高度有效。
- 未来研究应聚焦于确定最佳治疗时长并监测耐药风险。
研究设计与样本
- 前瞻性队列研究,在日本国立国际医疗研究中心开展,时间为2020年1月1日至2022年10月31日。
- 纳入生殖支原体泌尿生殖道或直肠感染且未接受初始西他沙星单药治疗的患者,共27例接受西他沙星联合多西环素21天挽救治疗。
- 对生殖支原体分离株检测parC、gyrA和23S rRNA耐药相关突变。
主要发现
- 所有可进行耐药分析的菌株均携带parC突变(24/24)和大环内酯耐药相关突变(25/25),68%(17/25)携带gyrA突变。
- 总体治愈率为77.8%。
- 对同时携带parC和gyrA突变的菌株,联合方案治愈率为68.8%,与单药治疗的37.5%相比P=0.053。
关键数值与推荐
- 总体治愈率77.8%。
- 同时携带parC和gyrA突变菌株的治愈率68.8%,与单药治疗37.5%相比P=0.053。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究应聚焦于确定最佳治疗时长并监测耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma genitalium, which causes sexually transmitted diseases, is increasingly resistant to key antibiotics such as macrolides and quinolones, posing a challenge for treatment. OBJECTIVES: To assess the effectiveness of prolonged sitafloxacin and doxycycline combination therapy as a new alternative treatment strategy for highly drug-resistant M. genitalium strains. METHODS: A prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan, from 1 January 2020 to 31 October 2022. Patients with M. genitalium urogenital or rectal infections and those who did not receive the initial sitafloxacin monotherapy were included. Patients were administered sitafloxacin and doxycycline for 21 days as salvage therapy. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations. RESULTS: Twenty-seven patients received the combination therapy. All M. genitalium strains available for resistance analysis had parC (24/24) and macrolide resistance-associated (25/25) mutations, and 68% (17/25) had gyrA mutations. The overall cure rate was 77.8%. For strains with concurrent parC and gyrA mutations, the cure rate was 68.8% (P = 0.053) compared with that for monotherapy (37.5%). CONCLUSIONS: Prolonged combination therapy is highly effective against M. genitalium strains with concurrent parC and gyrA mutations. Future research should focus on establishing the optimal treatment duration and monitoring the risk of resistance.
引用
- Ando N, Mizushima D, Takano M, et al. Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium. J Antimicrob Chemother. 2025. PMID: 39499214. doi:10.1093/jac/dkae403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。